Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lipoproteins

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Lipoproteins. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-018531-17 Sponsor Protocol Number: TRED012010 Start Date*: 2010-06-25
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Effect of Tredaptive on serum lipoproteins, lipoproteins metabolism, oxidative stress and HDL antioxidant function.
    Medical condition: Hypercholesterolaemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-015729-35 Sponsor Protocol Number: PCOS&Niacin Start Date*: 2009-11-23
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: TO DETERMINE IF CARDIOVASCULAR RISK INDICES INCLUDING POSTPRANDIAL HYPERTRIGLYCERIDAEMIA ARE MODIFIED FAVOURABLY BY NICOTINIC ACID (NIACIN) IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS)
    Medical condition: Polycystic ovary syndrome
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001372-12 Sponsor Protocol Number: 1100.1426 Start Date*: 2005-11-30
    Sponsor Name:Boehringer Ingelheim Netherlands B.V.
    Full Title: An open-label, non-randomized, single arm study, to investigate the mechanism(s) by which nevirapine increases plasma high density lipoproteins concentration in HIV + subjects treated with Viramune...
    Medical condition: Treatment of HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002332-15 Sponsor Protocol Number: D1840M00006 Start Date*: 2008-09-15
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the transthoracic Doppler echocardiography method as a non-invasive method for coronary function measurements; ability to detect sho...
    Medical condition: In this study the IMP, rosuvastatin, is used as a tool compound for creating favourable lipid-altering, anti-inflammatory or other pleiotropic effects which are believed to change coronary flow res...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000541-11 Sponsor Protocol Number: P-7282 Start Date*: 2005-03-31
    Sponsor Name:Slidgigtinstituttet A/S
    Full Title: Glukosaminsulfat og hyperkolesterolæmi
    Medical condition: Osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005565-18 Sponsor Protocol Number: P05019 Start Date*: 2007-04-02
    Sponsor Name:Research and Development Department, University Hospital of South Manchester NHS Foundation Trust
    Full Title: Efficacy and tolerability of Ezetimibe in cardiac transplant recipients taking Cyclosporin
    Medical condition: Hyperlipidaemia in patients folowing cardiac transplantation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10062060 Hyperlipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003718-10 Sponsor Protocol Number: 2014RISP-ID01 Start Date*: 2015-09-15
    Sponsor Name:UMCG
    Full Title: A placebo-controlled discontinuation trial of off-label used risperidone in people with intellectual disability
    Medical condition: no specific condition, we will investigate people with intellectual disability who have been using risperidone on an off-label basis for at least one year.
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-000577-65 Sponsor Protocol Number: 2993-114 Start Date*: 2004-08-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, randomized, open label, comparator-controlled, parallel-group, multicentre study to compare the effects of exenatide and insulin glargine on beta cell function and cardiovascular risk ma...
    Medical condition: Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-001899-32 Sponsor Protocol Number: RESINFENOL Start Date*: 2017-08-17
    Sponsor Name:Dr. Abelardo Aguilera Peralta
    Full Title: Crossover and randomized clinical trial on the effect of Resincolestiramine in the intestinal absorption of new uremic toxins in patients in hemodialysis with chronic renal insufficiency
    Medical condition: Chronic renal insufficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000099-27 Sponsor Protocol Number: HEAT01 Start Date*: 2017-04-26
    Sponsor Name:The Department of Urology
    Full Title: Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial
    Medical condition: Metastisc castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002687-41 Sponsor Protocol Number: TA-8995-AD-1 Start Date*: 2021-12-09
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients with Early Alzheimer’s Disease (Hetero/Homozygote APOE4 Carr...
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001876-32 Sponsor Protocol Number: SLN360-002 Start Date*: 2023-04-14
    Sponsor Name:Silence Therapeutics plc
    Full Title: A multi-centre, randomised, double-blind placebo-controlled, Phase 2 study to investigate efficacy, safety and tolerability of SLN360 in participants with elevated lipoprotein(a) at high risk of at...
    Medical condition: elevated lipoprotein (a) and high risk of atherosclerotic cardiovascular disease (ASCVD) events
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10022891 - Investigations 10054009 Lipoprotein (a) increased PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Ongoing) SK (Ongoing) DK (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000375-42 Sponsor Protocol Number: S339.2.001 Start Date*: 2008-02-21
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: A multi-center, double-blind, parallel-design, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of oral recombinant microbial lipase (SLV339) in subjects with pa...
    Medical condition: Pancreatic exocrine insufficiency due to chronic pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009093 Chronic pancreatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) SE (Prematurely Ended) HU (Prematurely Ended) CZ (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2016-003815-37 Sponsor Protocol Number: MDCO-PCS-16-01 Start Date*: 2017-02-24
    Sponsor Name:Novartis Pharma AG
    Full Title: An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and...
    Medical condition: Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000237-48 Sponsor Protocol Number: MiraBAT01 Start Date*: 2016-04-20
    Sponsor Name:Leiden University Medical Center
    Full Title: The effect of Mirabegron on brown adipose tissue in healthy young white Caucasian and South Asian men
    Medical condition: Obesity and dyslipidemia
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005473-36 Sponsor Protocol Number: Dezember2014Version2 Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects
    Medical condition: familial hypercholesterolemia
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003093-21 Sponsor Protocol Number: 20091977 Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Department I
    Full Title: Influence of combined therapy of niacin and statins on stem cell mobilization and inflammatory parameters in patients suffering from coronary artery disease – randomized clinical study -
    Medical condition: Have stable coronary artery disease (i.e. no acute event like myocardial infarction or PTCA less then 3 months ago)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003168-28 Sponsor Protocol Number: 77458 Start Date*: 2022-06-28
    Sponsor Name:Academic Medical Center (AMC), department of Internal Medicine
    Full Title: Impact of Triglyceride-Lowering on Inflammatory Activity in Patients with Hypertriglyceridemia
    Medical condition: - Hypertriglyceridemia - Inflammation - Lipoproteins
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007083-22 Sponsor Protocol Number: 37822681SCH2002, INT-1, 10 FEB 2009 Start Date*: 2008-10-01
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schiz...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-003551-30 Sponsor Protocol Number: August2016 Start Date*: 2017-03-02
    Sponsor Name:Universitätsklinikum Freiburg
    Full Title: Modeling of the impact of a PCSK9 inhibition on lipoproteins in patients with dyslipidemia
    Medical condition: dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10013317 Lipid metabolism disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA